Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MapLight Therapeutics, Inc.MPLT · Entity 5316 | Chief Discovery Officer | August 17, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MapLight Therapeutics, Inc.
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Voting Common StockSEC Table I · non-derivative | Direct | 180,926 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Grant · Acquired 6,020 · Balance 180,926 F1: Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on July 1, 2027, and 1/16th of the RSUs shall vest on each subsequent October 1, January 1, April 1 and July 1 thereafter, subject to the Reporting Person's continued service through each vesting date. F2: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.25 · Expires 2036-08-16 | Direct | 24,455 |
Reported balance
After 2026-08-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-17 · Grant · Acquired 24,455 · Balance 24,455 F3: 1/4th of the total shares underlying the option shall vest on July 1, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on July 1, 2027, and 1/16th of the RSUs shall vest on each subsequent October 1, January 1, April 1 and July 1 thereafter, subject to the Reporting Person's continued service through each vesting date.
F2: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.
F3: 1/4th of the total shares underlying the option shall vest on July 1, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 19, 2026 22:35 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantEmployee Stock Option (right to buy) · Derivative | 24,455 | $0.00 Strike: $11.25 | $0.00 |
DisclosureSEC source: 0002021238-26-000012 · form4-08192026_060813.xml · derivative · entry 2 Kreitzer Anatol · CIK 0002021238 · Chief Discovery Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,455 Underlying: Voting Common Stock · 24,455 shares Expires 2036-08-16 F3 · derivative.exercise_date: 1/4th of the total shares underlying the option shall vest on July 1, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 22:35 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantVoting Common Stock | 6,020 | $0.00 | $0.00 |
DisclosureSEC source: 0002021238-26-000012 · form4-08192026_060813.xml · nonDerivative · entry 1 Kreitzer Anatol · CIK 0002021238 · Chief Discovery Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,926 F1 · shares: Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on July 1, 2027, and 1/16th of the RSUs shall vest on each subsequent October 1, January 1, April 1 and July 1 thereafter, subject to the Reporting Person's continued service through each vesting date. F2 · price: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. Read SEC document |
| July 17, 2026 Filed Jul 20, 2026 10:00 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 200 | $38.39 | $7,678.00 |
DisclosureSEC source: 0002021238-26-000010 · form4-07202026_060701.xml · nonDerivative · entry 7 Kreitzer Anatol · CIK 0002021238 · Chief Discovery Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 174,906 F6 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 24, 2025. F6 · shares: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 24, 2025. Read SEC document |
| July 17, 2026 Filed Jul 20, 2026 10:00 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 14,140 | $37.70 | $533,078.00 |
DisclosureSEC source: 0002021238-26-000010 · form4-07202026_060701.xml · nonDerivative · entry 6 Kreitzer Anatol · CIK 0002021238 · Chief Discovery Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,106 F6 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 24, 2025. F6 · shares: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 24, 2025. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.36 to $38.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 17, 2026 Filed Jul 20, 2026 10:00 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 2,833 | $37.05 | $104,962.65 |
DisclosureSEC source: 0002021238-26-000010 · form4-07202026_060701.xml · nonDerivative · entry 5 Kreitzer Anatol · CIK 0002021238 · Chief Discovery Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,246 F6 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 24, 2025. F6 · shares: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 24, 2025. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.36 to $37.335 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 10:00 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 1,592 | $37.44 | $59,604.48 |
DisclosureSEC source: 0002021238-26-000010 · form4-07202026_060701.xml · nonDerivative · entry 4 Kreitzer Anatol · CIK 0002021238 · Chief Discovery Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,079 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.26 to $37.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 10:00 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 7,464 | $36.66 | $273,630.24 |
DisclosureSEC source: 0002021238-26-000010 · form4-07202026_060701.xml · nonDerivative · entry 3 Kreitzer Anatol · CIK 0002021238 · Chief Discovery Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 193,671 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.12 to $37.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 15, 2026 Filed Jul 20, 2026 10:00 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 4,510 | $36.94 | $166,599.40 |
DisclosureSEC source: 0002021238-26-000010 · form4-07202026_060701.xml · nonDerivative · entry 2 Kreitzer Anatol · CIK 0002021238 · Chief Discovery Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 201,135 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.68 to $37.325 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 15, 2026 Filed Jul 20, 2026 10:00 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 5,545 | $36.13 | $200,340.85 |
DisclosureSEC source: 0002021238-26-000010 · form4-07202026_060701.xml · nonDerivative · entry 1 Kreitzer Anatol · CIK 0002021238 · Chief Discovery Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,645 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.68 to $36.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 27, 2026 Filed Apr 29, 2026 20:30 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 7,821 | $30.50 | $238,540.50 |
DisclosureSEC source: 0002021238-26-000008 · form4-04292026_040429.xml · nonDerivative · entry 3 Kreitzer Anatol · CIK 0002021238 · Chief Discovery Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,190 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 24, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.27 to $30.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 27, 2026 Filed Apr 29, 2026 20:30 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 29,255 | $29.63 | $866,825.65 |
DisclosureSEC source: 0002021238-26-000008 · form4-04292026_040429.xml · nonDerivative · entry 2 Kreitzer Anatol · CIK 0002021238 · Chief Discovery Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 219,011 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 24, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.27 to $30.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 27, 2026 Filed Apr 29, 2026 20:30 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 8,346 | $28.96 | $241,700.16 |
DisclosureSEC source: 0002021238-26-000008 · form4-04292026_040429.xml · nonDerivative · entry 1 Kreitzer Anatol · CIK 0002021238 · Chief Discovery Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 248,266 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 24, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.27 to $29.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:05 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 3,316 | $26.61 | $88,238.76 |
DisclosureSEC source: 0002021238-26-000006 · form4-04172026_040415.xml · nonDerivative · entry 1 Kreitzer Anatol · CIK 0002021238 · Chief Discovery Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,612 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.6045 to $26.6093 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 22:50 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantEmployee Stock Option (right to buy) · Derivative | 24,455 | $0.00 Strike: $15.70 | $0.00 |
DisclosureSEC source: 0002021238-26-000004 · form4-02092026_050207.xml · derivative · entry 2 Kreitzer Anatol · CIK 0002021238 · Chief Discovery Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,455 Underlying: Voting Common Stock · 24,455 shares Expires 2036-02-04 F3 · derivative.exercise_date: 1/4th of the total shares underlying the option shall vest on February 5, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 22:50 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantVoting Common Stock | 6,020 | $0.00 | $0.00 |
DisclosureSEC source: 0002021238-26-000004 · form4-02092026_050207.xml · nonDerivative · entry 1 Kreitzer Anatol · CIK 0002021238 · Chief Discovery Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 259,928 F1 · shares: Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on January 1, 2027, and 1/16th of the RSUs shall vest on each subsequent April 1, July 1, October 1 and January 1 thereafter, subject to the Reporting Person's continued service through each vesting date. F2 · price: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:30 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | Tax withholdingVoting Common Stock | 42,099 | $17.98 | $756,940.02 |
DisclosureSEC source: 0002021238-26-000002 · form4-01292026_040109.xml · nonDerivative · entry 1 Kreitzer Anatol · CIK 0002021238 · Chief Discovery Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,908 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock unit awards. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025. Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 20:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantEmployee Stock Option (right to buy) · Derivative | 146,052 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0002021238-25-000006 · form4-10282025_041012.xml · derivative · entry 2 Kreitzer Anatol · CIK 0002021238 · Chief Discovery Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,052 Underlying: Voting Common Stock · 146,052 shares Expires 2035-10-26 F3 · derivative.exercise_date: 1/4th of the total shares underlying the option shall vest on October 1, 2026, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 20:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantVoting Common Stock | 35,953 | $0.00 | $0.00 |
DisclosureSEC source: 0002021238-25-000006 · form4-10282025_041012.xml · nonDerivative · entry 1 Kreitzer Anatol · CIK 0002021238 · Chief Discovery Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,953 F1 · shares: Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on October 1, 2026, and 1/16th of the RSUs shall vest on each subsequent January 1, April 1, July 1 and October 1 thereafter, subject to the Reporting Person's continued service through each vesting date. F2 · price: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.